Prolidase deficiency

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:742OMIM:170100E72.8
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Prolidase deficiency (also known as peptidase D deficiency or imidodipeptidase deficiency) is a rare autosomal recessive metabolic disorder caused by mutations in the PEPD gene, which encodes the enzyme prolidase. This enzyme is essential for the final step in the degradation of imidodipeptides containing proline or hydroxyproline, particularly those derived from collagen breakdown. When prolidase is deficient, these dipeptides accumulate in body fluids and are excreted in massive amounts in the urine (iminodipeptiduria). Because collagen is a major structural protein throughout the body, the disorder affects multiple organ systems. The hallmark clinical feature is chronic, recalcitrant skin ulceration, predominantly affecting the lower extremities, which is often severe and resistant to conventional wound care. Other key manifestations include recurrent respiratory infections, splenomegaly, intellectual disability of variable severity, and characteristic facial features. Patients may also develop autoimmune phenomena, including systemic lupus erythematosus-like features, as well as chronic lung disease, anemia, thrombocytopenia, and hypergammaglobulinemia. The clinical presentation is highly variable, even among affected siblings, ranging from asymptomatic individuals to those with severe, debilitating disease. There is no definitive cure for prolidase deficiency. Treatment is largely supportive and symptomatic, focusing on wound management for skin ulcers, treatment of infections, and management of autoimmune complications. Various therapeutic approaches have been attempted, including topical and systemic proline and glycine supplementation, blood transfusions with erythrocytes containing functional prolidase (enzyme replacement via carrier erythrocytes), ascorbic acid, manganese supplementation, and growth hormone therapy, with variable and often limited success. Early diagnosis through measurement of prolidase enzyme activity in leukocytes or fibroblasts and identification of PEPD gene mutations is important for appropriate management and genetic counseling.

Also known as:

Clinical phenotype terms— hover any for plain English:

Abnormality of the middle earHP:0000370
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Prolidase deficiency.

View clinical trials →

No actively recruiting trials found for Prolidase deficiency at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Prolidase deficiency community →

Specialists

1 foundView all specialists →
AM
Abdulkadir TUNÇ, MD
Specialist
PI on 1 active trial1 Prolidase deficiency publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Prolidase deficiency.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Prolidase deficiencyForum →

No community posts yet. Be the first to share your experience with Prolidase deficiency.

Start the conversation →

Latest news about Prolidase deficiency

No recent news articles for Prolidase deficiency.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Prolidase deficiency

What is Prolidase deficiency?

Prolidase deficiency (also known as peptidase D deficiency or imidodipeptidase deficiency) is a rare autosomal recessive metabolic disorder caused by mutations in the PEPD gene, which encodes the enzyme prolidase. This enzyme is essential for the final step in the degradation of imidodipeptides containing proline or hydroxyproline, particularly those derived from collagen breakdown. When prolidase is deficient, these dipeptides accumulate in body fluids and are excreted in massive amounts in the urine (iminodipeptiduria). Because collagen is a major structural protein throughout the body, the

How is Prolidase deficiency inherited?

Prolidase deficiency follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Which specialists treat Prolidase deficiency?

1 specialists and care centers treating Prolidase deficiency are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.